Meeting
2023 ASCO Annual Meeting
3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.
Authors
Emeline Tabouret
Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service de Neurooncologie, Marseille, France
Emeline Tabouret , Julia Furtner , Thomas Graillon , Antonio Silvani , Emilie Le Rhun , Riccardo Soffietti , Giuseppe Lombardi , Juan Manuel Sepulveda , Petter Brandal , Lucy Brazil , Martin Bendszus , Vassilis Golfinopoulos , Thierry Gorlia , Michael Weller , Felix Sahm , Wolfgang Wick , Matthias Preusser
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Non-Glioma
Clinical Trial Registration Number
NCT02234050
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2075)
DOI
10.1200/JCO.2023.41.16_suppl.2075
Abstract #
2075
Poster Bd #
432
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.
First Author: Kristina Fanucci
Poster
2023 ASCO Annual Meeting
Abemaciclib in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and/or CCND1 and/or CDK6 amplification: A phase II multicenter trial.
First Author: Jerome Fayette
Poster
2020 ASCO Virtual Scientific Program
Accelerator-based BNCT in rescue treatment of patients with recurrent GBM: A multicenter phase II study.
First Author: Shin-Ichi Miyatake
Poster
2012 ASCO Annual Meeting
Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.
First Author: Annick Desjardins